^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SORT1 positive

    i
    Other names: SORT1, Sortilin 1, Neurotensin Receptor 3, 100 KDa NT Receptor, Glycoprotein 95, Sortilin, Gp95, NTR3, NT3, LDLCQ6
    Entrez ID:
    6272
    Related biomarkers:
    Expression
    Mutation
    over2years
    TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. (PubMed, Cancer Sci)
    Altogether, the data demonstrates the high in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism. This property allows for selective treatment of SORT1-positive TNBC and makes TH1902 a promising avenue for personalized therapy with the potential of improving the therapeutic window of cytotoxic anticancer drugs such as docetaxel.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BCL2L1 (BCL2-like 1) • SORT1 (Sortilin 1)
    |
    SORT1 positive
    |
    docetaxel • sudocetaxel zendusortide (TH 1902)
    3years
    [VIRTUAL] TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers (AACR 2021)
    In all cases, TH1902 showed more potent inhibition than Docetaxel. These results strongly support future clinical development of TH1902 as novel therapeutics in SORT1+ cancers.
    Preclinical
    |
    SORT1 (Sortilin 1)
    |
    SORT1 expression • SORT1 positive
    |
    docetaxel • sudocetaxel zendusortide (TH 1902)